Relation of severe COVID-19 to polypharmacy and prescribing of psychotropic drugs: the REACT-SCOT case-control study
Background The objective of this study was to investigate the relation of severe COVID-19 to prior drug prescribing. Methods Severe cases were defined by entry to critical care or fatal outcome. For this matched case-control study (REACT-SCOT), all 4251 cases of severe COVID-19 in Scotland since the...
Saved in:
| Published in: | BMC medicine Vol. 19; no. 1; pp. 51 - 11 |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
London
BioMed Central
22.02.2021
BioMed Central Ltd Springer Nature B.V BMC |
| Subjects: | |
| ISSN: | 1741-7015, 1741-7015 |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Background
The objective of this study was to investigate the relation of severe COVID-19 to prior drug prescribing.
Methods
Severe cases were defined by entry to critical care or fatal outcome. For this matched case-control study (REACT-SCOT), all 4251 cases of severe COVID-19 in Scotland since the start of the epidemic were matched for age, sex and primary care practice to 36,738 controls from the population register. Records were linked to hospital discharges since June 2015 and dispensed prescriptions issued in primary care during the last 240 days.
Results
Severe COVID-19 was strongly associated with the number of non-cardiovascular drug classes dispensed. This association was strongest in those not resident in a care home, in whom the rate ratio (95% CI) associated with dispensing of 12 or more drug classes versus none was 10.8 (8.8, 13.3), and in those without any of the conditions designated as conferring increased risk of COVID-19. Of 17 drug classes postulated at the start of the epidemic to be “medications compromising COVID”, all were associated with increased risk of severe COVID-19 and these associations were present in those without any of the designated risk conditions. The fraction of cases in the population attributable to exposure to these drug classes was 38%. The largest effect was for antipsychotic agents: rate ratio 4.18 (3.42, 5.11). Other drug classes with large effects included proton pump inhibitors (rate ratio 2.20 (1.72, 2.83) for = 2 defined daily doses/day), opioids (3.66 (2.68, 5.01) for = 50 mg morphine equivalent/day) and gabapentinoids. These associations persisted after adjusting for covariates and were stronger with recent than with non-recent exposure.
Conclusions
Severe COVID-19 is associated with polypharmacy and with drugs that cause sedation, respiratory depression, or dyskinesia; have anticholinergic effects; or affect the gastrointestinal system. These associations are not easily explained by co-morbidity. Measures to reduce the burden of mortality and morbidity from COVID-19 should include reinforcing existing guidance on reducing overprescribing of these drug classes and limiting inappropriate polypharmacy.
Registration
ENCEPP number https://EUPAS35558 |
|---|---|
| AbstractList | Background The objective of this study was to investigate the relation of severe COVID-19 to prior drug prescribing. Methods Severe cases were defined by entry to critical care or fatal outcome. For this matched case-control study (REACT-SCOT), all 4251 cases of severe COVID-19 in Scotland since the start of the epidemic were matched for age, sex and primary care practice to 36,738 controls from the population register. Records were linked to hospital discharges since June 2015 and dispensed prescriptions issued in primary care during the last 240 days. Results Severe COVID-19 was strongly associated with the number of non-cardiovascular drug classes dispensed. This association was strongest in those not resident in a care home, in whom the rate ratio (95% CI) associated with dispensing of 12 or more drug classes versus none was 10.8 (8.8, 13.3), and in those without any of the conditions designated as conferring increased risk of COVID-19. Of 17 drug classes postulated at the start of the epidemic to be "medications compromising COVID", all were associated with increased risk of severe COVID-19 and these associations were present in those without any of the designated risk conditions. The fraction of cases in the population attributable to exposure to these drug classes was 38%. The largest effect was for antipsychotic agents: rate ratio 4.18 (3.42, 5.11). Other drug classes with large effects included proton pump inhibitors (rate ratio 2.20 (1.72, 2.83) for = 2 defined daily doses/day), opioids (3.66 (2.68, 5.01) for = 50 mg morphine equivalent/day) and gabapentinoids. These associations persisted after adjusting for covariates and were stronger with recent than with non-recent exposure. Conclusions Severe COVID-19 is associated with polypharmacy and with drugs that cause sedation, respiratory depression, or dyskinesia; have anticholinergic effects; or affect the gastrointestinal system. These associations are not easily explained by co-morbidity. Measures to reduce the burden of mortality and morbidity from COVID-19 should include reinforcing existing guidance on reducing overprescribing of these drug classes and limiting inappropriate polypharmacy. Registration ENCEPP number Keywords: COVID-19, Pharmacoepidemiology, Antipsychotic agents, Opioids, Gabapentinoids, Proton pump inhibitors, Polypharmacy, Overprescribing The objective of this study was to investigate the relation of severe COVID-19 to prior drug prescribing.BACKGROUNDThe objective of this study was to investigate the relation of severe COVID-19 to prior drug prescribing.Severe cases were defined by entry to critical care or fatal outcome. For this matched case-control study (REACT-SCOT), all 4251 cases of severe COVID-19 in Scotland since the start of the epidemic were matched for age, sex and primary care practice to 36,738 controls from the population register. Records were linked to hospital discharges since June 2015 and dispensed prescriptions issued in primary care during the last 240 days.METHODSSevere cases were defined by entry to critical care or fatal outcome. For this matched case-control study (REACT-SCOT), all 4251 cases of severe COVID-19 in Scotland since the start of the epidemic were matched for age, sex and primary care practice to 36,738 controls from the population register. Records were linked to hospital discharges since June 2015 and dispensed prescriptions issued in primary care during the last 240 days.Severe COVID-19 was strongly associated with the number of non-cardiovascular drug classes dispensed. This association was strongest in those not resident in a care home, in whom the rate ratio (95% CI) associated with dispensing of 12 or more drug classes versus none was 10.8 (8.8, 13.3), and in those without any of the conditions designated as conferring increased risk of COVID-19. Of 17 drug classes postulated at the start of the epidemic to be "medications compromising COVID", all were associated with increased risk of severe COVID-19 and these associations were present in those without any of the designated risk conditions. The fraction of cases in the population attributable to exposure to these drug classes was 38%. The largest effect was for antipsychotic agents: rate ratio 4.18 (3.42, 5.11). Other drug classes with large effects included proton pump inhibitors (rate ratio 2.20 (1.72, 2.83) for = 2 defined daily doses/day), opioids (3.66 (2.68, 5.01) for = 50 mg morphine equivalent/day) and gabapentinoids. These associations persisted after adjusting for covariates and were stronger with recent than with non-recent exposure.RESULTSSevere COVID-19 was strongly associated with the number of non-cardiovascular drug classes dispensed. This association was strongest in those not resident in a care home, in whom the rate ratio (95% CI) associated with dispensing of 12 or more drug classes versus none was 10.8 (8.8, 13.3), and in those without any of the conditions designated as conferring increased risk of COVID-19. Of 17 drug classes postulated at the start of the epidemic to be "medications compromising COVID", all were associated with increased risk of severe COVID-19 and these associations were present in those without any of the designated risk conditions. The fraction of cases in the population attributable to exposure to these drug classes was 38%. The largest effect was for antipsychotic agents: rate ratio 4.18 (3.42, 5.11). Other drug classes with large effects included proton pump inhibitors (rate ratio 2.20 (1.72, 2.83) for = 2 defined daily doses/day), opioids (3.66 (2.68, 5.01) for = 50 mg morphine equivalent/day) and gabapentinoids. These associations persisted after adjusting for covariates and were stronger with recent than with non-recent exposure.Severe COVID-19 is associated with polypharmacy and with drugs that cause sedation, respiratory depression, or dyskinesia; have anticholinergic effects; or affect the gastrointestinal system. These associations are not easily explained by co-morbidity. Measures to reduce the burden of mortality and morbidity from COVID-19 should include reinforcing existing guidance on reducing overprescribing of these drug classes and limiting inappropriate polypharmacy.CONCLUSIONSSevere COVID-19 is associated with polypharmacy and with drugs that cause sedation, respiratory depression, or dyskinesia; have anticholinergic effects; or affect the gastrointestinal system. These associations are not easily explained by co-morbidity. Measures to reduce the burden of mortality and morbidity from COVID-19 should include reinforcing existing guidance on reducing overprescribing of these drug classes and limiting inappropriate polypharmacy.ENCEPP number EUPAS35558.REGISTRATIONENCEPP number EUPAS35558. Background The objective of this study was to investigate the relation of severe COVID-19 to prior drug prescribing. Methods Severe cases were defined by entry to critical care or fatal outcome. For this matched case-control study (REACT-SCOT), all 4251 cases of severe COVID-19 in Scotland since the start of the epidemic were matched for age, sex and primary care practice to 36,738 controls from the population register. Records were linked to hospital discharges since June 2015 and dispensed prescriptions issued in primary care during the last 240 days. Results Severe COVID-19 was strongly associated with the number of non-cardiovascular drug classes dispensed. This association was strongest in those not resident in a care home, in whom the rate ratio (95% CI) associated with dispensing of 12 or more drug classes versus none was 10.8 (8.8, 13.3), and in those without any of the conditions designated as conferring increased risk of COVID-19. Of 17 drug classes postulated at the start of the epidemic to be “medications compromising COVID”, all were associated with increased risk of severe COVID-19 and these associations were present in those without any of the designated risk conditions. The fraction of cases in the population attributable to exposure to these drug classes was 38%. The largest effect was for antipsychotic agents: rate ratio 4.18 (3.42, 5.11). Other drug classes with large effects included proton pump inhibitors (rate ratio 2.20 (1.72, 2.83) for = 2 defined daily doses/day), opioids (3.66 (2.68, 5.01) for = 50 mg morphine equivalent/day) and gabapentinoids. These associations persisted after adjusting for covariates and were stronger with recent than with non-recent exposure. Conclusions Severe COVID-19 is associated with polypharmacy and with drugs that cause sedation, respiratory depression, or dyskinesia; have anticholinergic effects; or affect the gastrointestinal system. These associations are not easily explained by co-morbidity. Measures to reduce the burden of mortality and morbidity from COVID-19 should include reinforcing existing guidance on reducing overprescribing of these drug classes and limiting inappropriate polypharmacy. Registration ENCEPP number EUPAS35558 Background The objective of this study was to investigate the relation of severe COVID-19 to prior drug prescribing. Methods Severe cases were defined by entry to critical care or fatal outcome. For this matched case-control study (REACT-SCOT), all 4251 cases of severe COVID-19 in Scotland since the start of the epidemic were matched for age, sex and primary care practice to 36,738 controls from the population register. Records were linked to hospital discharges since June 2015 and dispensed prescriptions issued in primary care during the last 240 days. Results Severe COVID-19 was strongly associated with the number of non-cardiovascular drug classes dispensed. This association was strongest in those not resident in a care home, in whom the rate ratio (95% CI) associated with dispensing of 12 or more drug classes versus none was 10.8 (8.8, 13.3), and in those without any of the conditions designated as conferring increased risk of COVID-19. Of 17 drug classes postulated at the start of the epidemic to be “medications compromising COVID”, all were associated with increased risk of severe COVID-19 and these associations were present in those without any of the designated risk conditions. The fraction of cases in the population attributable to exposure to these drug classes was 38%. The largest effect was for antipsychotic agents: rate ratio 4.18 (3.42, 5.11). Other drug classes with large effects included proton pump inhibitors (rate ratio 2.20 (1.72, 2.83) for = 2 defined daily doses/day), opioids (3.66 (2.68, 5.01) for = 50 mg morphine equivalent/day) and gabapentinoids. These associations persisted after adjusting for covariates and were stronger with recent than with non-recent exposure. Conclusions Severe COVID-19 is associated with polypharmacy and with drugs that cause sedation, respiratory depression, or dyskinesia; have anticholinergic effects; or affect the gastrointestinal system. These associations are not easily explained by co-morbidity. Measures to reduce the burden of mortality and morbidity from COVID-19 should include reinforcing existing guidance on reducing overprescribing of these drug classes and limiting inappropriate polypharmacy. Registration ENCEPP number https://EUPAS35558 The objective of this study was to investigate the relation of severe COVID-19 to prior drug prescribing. Severe cases were defined by entry to critical care or fatal outcome. For this matched case-control study (REACT-SCOT), all 4251 cases of severe COVID-19 in Scotland since the start of the epidemic were matched for age, sex and primary care practice to 36,738 controls from the population register. Records were linked to hospital discharges since June 2015 and dispensed prescriptions issued in primary care during the last 240 days. Severe COVID-19 was strongly associated with the number of non-cardiovascular drug classes dispensed. This association was strongest in those not resident in a care home, in whom the rate ratio (95% CI) associated with dispensing of 12 or more drug classes versus none was 10.8 (8.8, 13.3), and in those without any of the conditions designated as conferring increased risk of COVID-19. Of 17 drug classes postulated at the start of the epidemic to be "medications compromising COVID", all were associated with increased risk of severe COVID-19 and these associations were present in those without any of the designated risk conditions. The fraction of cases in the population attributable to exposure to these drug classes was 38%. The largest effect was for antipsychotic agents: rate ratio 4.18 (3.42, 5.11). Other drug classes with large effects included proton pump inhibitors (rate ratio 2.20 (1.72, 2.83) for = 2 defined daily doses/day), opioids (3.66 (2.68, 5.01) for = 50 mg morphine equivalent/day) and gabapentinoids. These associations persisted after adjusting for covariates and were stronger with recent than with non-recent exposure. Severe COVID-19 is associated with polypharmacy and with drugs that cause sedation, respiratory depression, or dyskinesia; have anticholinergic effects; or affect the gastrointestinal system. These associations are not easily explained by co-morbidity. Measures to reduce the burden of mortality and morbidity from COVID-19 should include reinforcing existing guidance on reducing overprescribing of these drug classes and limiting inappropriate polypharmacy. Abstract Background The objective of this study was to investigate the relation of severe COVID-19 to prior drug prescribing. Methods Severe cases were defined by entry to critical care or fatal outcome. For this matched case-control study (REACT-SCOT), all 4251 cases of severe COVID-19 in Scotland since the start of the epidemic were matched for age, sex and primary care practice to 36,738 controls from the population register. Records were linked to hospital discharges since June 2015 and dispensed prescriptions issued in primary care during the last 240 days. Results Severe COVID-19 was strongly associated with the number of non-cardiovascular drug classes dispensed. This association was strongest in those not resident in a care home, in whom the rate ratio (95% CI) associated with dispensing of 12 or more drug classes versus none was 10.8 (8.8, 13.3), and in those without any of the conditions designated as conferring increased risk of COVID-19. Of 17 drug classes postulated at the start of the epidemic to be “medications compromising COVID”, all were associated with increased risk of severe COVID-19 and these associations were present in those without any of the designated risk conditions. The fraction of cases in the population attributable to exposure to these drug classes was 38%. The largest effect was for antipsychotic agents: rate ratio 4.18 (3.42, 5.11). Other drug classes with large effects included proton pump inhibitors (rate ratio 2.20 (1.72, 2.83) for = 2 defined daily doses/day), opioids (3.66 (2.68, 5.01) for = 50 mg morphine equivalent/day) and gabapentinoids. These associations persisted after adjusting for covariates and were stronger with recent than with non-recent exposure. Conclusions Severe COVID-19 is associated with polypharmacy and with drugs that cause sedation, respiratory depression, or dyskinesia; have anticholinergic effects; or affect the gastrointestinal system. These associations are not easily explained by co-morbidity. Measures to reduce the burden of mortality and morbidity from COVID-19 should include reinforcing existing guidance on reducing overprescribing of these drug classes and limiting inappropriate polypharmacy. Registration ENCEPP number EUPAS35558 The objective of this study was to investigate the relation of severe COVID-19 to prior drug prescribing. Severe cases were defined by entry to critical care or fatal outcome. For this matched case-control study (REACT-SCOT), all 4251 cases of severe COVID-19 in Scotland since the start of the epidemic were matched for age, sex and primary care practice to 36,738 controls from the population register. Records were linked to hospital discharges since June 2015 and dispensed prescriptions issued in primary care during the last 240 days. Severe COVID-19 was strongly associated with the number of non-cardiovascular drug classes dispensed. This association was strongest in those not resident in a care home, in whom the rate ratio (95% CI) associated with dispensing of 12 or more drug classes versus none was 10.8 (8.8, 13.3), and in those without any of the conditions designated as conferring increased risk of COVID-19. Of 17 drug classes postulated at the start of the epidemic to be "medications compromising COVID", all were associated with increased risk of severe COVID-19 and these associations were present in those without any of the designated risk conditions. The fraction of cases in the population attributable to exposure to these drug classes was 38%. The largest effect was for antipsychotic agents: rate ratio 4.18 (3.42, 5.11). Other drug classes with large effects included proton pump inhibitors (rate ratio 2.20 (1.72, 2.83) for = 2 defined daily doses/day), opioids (3.66 (2.68, 5.01) for = 50 mg morphine equivalent/day) and gabapentinoids. These associations persisted after adjusting for covariates and were stronger with recent than with non-recent exposure. Severe COVID-19 is associated with polypharmacy and with drugs that cause sedation, respiratory depression, or dyskinesia; have anticholinergic effects; or affect the gastrointestinal system. These associations are not easily explained by co-morbidity. Measures to reduce the burden of mortality and morbidity from COVID-19 should include reinforcing existing guidance on reducing overprescribing of these drug classes and limiting inappropriate polypharmacy. ENCEPP number EUPAS35558. |
| ArticleNumber | 51 |
| Audience | Academic |
| Author | Lone, Nazir McKeigue, Paul M. Weir, Amanda Caparrotta, Thomas M. Wood, Rachael Goldberg, David Guthrie, Bruce Kennedy, Sharon McMenamin, Jim Hutchinson, Sharon McGurnaghan, Stuart J. Colhoun, Helen M. Robertson, Chris Smith-Palmer, Alison Bishop, Jen McAllister, David Murray, Janet |
| Author_xml | – sequence: 1 givenname: Paul M. orcidid: 0000-0002-5217-1034 surname: McKeigue fullname: McKeigue, Paul M. email: paul.mckeigue@ed.ac.uk organization: Usher Institute, College of Medicine and Veterinary Medicine, University of Edinburgh, Public Health Scotland, Meridian Court – sequence: 2 givenname: Sharon surname: Kennedy fullname: Kennedy, Sharon organization: NHS Information Services Division (Public Health Scotland), Gyle Square – sequence: 3 givenname: Amanda surname: Weir fullname: Weir, Amanda organization: Public Health Scotland, Meridian Court – sequence: 4 givenname: Jen surname: Bishop fullname: Bishop, Jen organization: Public Health Scotland, Meridian Court – sequence: 5 givenname: Stuart J. surname: McGurnaghan fullname: McGurnaghan, Stuart J. organization: Institute of Genetics and Molecular Medicine, College of Medicine and Veterinary Medicine, University of Edinburgh, Western General Hospital Campus – sequence: 6 givenname: David surname: McAllister fullname: McAllister, David organization: Public Health Scotland, Meridian Court, Institute of Health and Wellbeing, University of Glasgow – sequence: 7 givenname: Chris surname: Robertson fullname: Robertson, Chris organization: Public Health Scotland, Meridian Court, Department of Mathematics and Statistics, University of Strathclyde – sequence: 8 givenname: Rachael surname: Wood fullname: Wood, Rachael organization: NHS Information Services Division (Public Health Scotland), Gyle Square – sequence: 9 givenname: Nazir surname: Lone fullname: Lone, Nazir organization: Usher Institute, College of Medicine and Veterinary Medicine, University of Edinburgh – sequence: 10 givenname: Janet surname: Murray fullname: Murray, Janet organization: Public Health Scotland, Meridian Court – sequence: 11 givenname: Thomas M. surname: Caparrotta fullname: Caparrotta, Thomas M. organization: Institute of Genetics and Molecular Medicine, College of Medicine and Veterinary Medicine, University of Edinburgh, Western General Hospital Campus – sequence: 12 givenname: Alison surname: Smith-Palmer fullname: Smith-Palmer, Alison organization: Public Health Scotland, Meridian Court – sequence: 13 givenname: David surname: Goldberg fullname: Goldberg, David organization: Public Health Scotland, Meridian Court – sequence: 14 givenname: Jim surname: McMenamin fullname: McMenamin, Jim organization: Public Health Scotland, Meridian Court – sequence: 15 givenname: Bruce surname: Guthrie fullname: Guthrie, Bruce organization: Usher Institute, College of Medicine and Veterinary Medicine, University of Edinburgh – sequence: 16 givenname: Sharon surname: Hutchinson fullname: Hutchinson, Sharon organization: Public Health Scotland, Meridian Court, School of Health and Life Sciences, Glasgow Caledonian University – sequence: 17 givenname: Helen M. surname: Colhoun fullname: Colhoun, Helen M. organization: Public Health Scotland, Meridian Court, Institute of Genetics and Molecular Medicine, College of Medicine and Veterinary Medicine, University of Edinburgh, Western General Hospital Campus |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33612113$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kl1r2zAYhc3oWD-2P7CLIRiM3bjThy3JuxiErNsChUCX7VbI8mtbxbE8yS7k309J2jUpo_jC5vVzDtJ5z3ly0rsekuQtwZeESP4pEFoQnmJKUkwKLFL5IjkjIiOpwCQ_Ofg-Tc5DuMWY5kJkr5JTxjihhLCzZLyBTo_W9cjVKMAdeEDz5e_F15QUaHRocN1maLVfa7NBuq_Q4CEYb0vbN1vJEDamdaN3gzWo8lMTPqOxBXRzNZuv0p_z5QoZHSA1ro9Qh8I4VZvXyctadwHe3L8vkl_frlbzH-n18vtiPrtOjcDZmIqCQkEYL_OSlzQentWkyKSmBuM6h9yUGHMuslLKCJRaMmmqODUsq0suC3aRLPa-ldO3avB2rf1GOW3VbuB8o7QfrelAlaaSNC8yITTNolxLoysOBgtTEl7r6PVl7zVM5RoqA_E-ujsyPf7T21Y17k4JWYic8Gjw8d7Auz8ThFGtbTDQdboHNwVFs4JSyXHBIvr-CXrrJt_HqBTNMeVZXF72SDU6XsD2dVyDNltTNeM54yxnbJvB5X-o-FSwtnErUNs4PxJ8OBC0oLuxDa6btiUJx-C7w0T-RfFQrgjIPWC8C8FDrYwdd2WLR7CdIlhte6z2PVaxx2rXYyWjlD6RPrg_K2J7UYhw34B_jO0Z1V_AWwJq |
| CitedBy_id | crossref_primary_10_1186_s41182_022_00456_x crossref_primary_10_1016_S2215_0366_21_00232_7 crossref_primary_10_3390_tropicalmed7030037 crossref_primary_10_1016_j_bbih_2021_100353 crossref_primary_10_1016_j_biopha_2024_116242 crossref_primary_10_4274_ejgg_galenos_2021_2021_11_3 crossref_primary_10_1186_s12889_023_16993_x crossref_primary_10_1016_j_aprim_2022_102463 crossref_primary_10_3389_fpsyt_2022_1052710 crossref_primary_10_3389_fcimb_2022_935280 crossref_primary_10_3390_pharmaceutics14091828 crossref_primary_10_1007_s10072_021_05315_x crossref_primary_10_1093_ageing_afae082 crossref_primary_10_7759_cureus_48834 crossref_primary_10_1016_S2213_2600_22_00045_5 crossref_primary_10_1038_s41440_024_01682_y crossref_primary_10_1007_s41999_022_00723_4 crossref_primary_10_1002_hup_2789 crossref_primary_10_1007_s13300_024_01681_9 crossref_primary_10_1016_j_cmi_2024_06_019 crossref_primary_10_1007_s40264_022_01266_0 crossref_primary_10_1186_s12877_022_03571_w crossref_primary_10_1016_j_japh_2021_05_006 crossref_primary_10_1007_s00228_022_03319_w crossref_primary_10_3389_fimmu_2024_1341168 crossref_primary_10_3390_jcm11144038 crossref_primary_10_1136_bmjopen_2021_060295 crossref_primary_10_3390_ijerph18158168 crossref_primary_10_1002_jcph_1949 crossref_primary_10_1002_jgh3_12905 crossref_primary_10_1016_j_euroneuro_2022_10_004 crossref_primary_10_3390_pharmaceutics13091513 |
| Cites_doi | 10.2174/157488410793352067 10.7326/0003-4819-152-7-201004060-00006 10.1111/joim.12186 10.1001/jamainternmed.2018.6101 10.1186/1471-2296-15-58 10.1056/NEJMoa2006923 10.1186/s12913-018-3358-5 10.23889/ijpds.v4i3.1230 10.1093/oxfordjournals.aje.a114174 10.1016/j.japh.2017.06.002 10.1371/journal.pmed.1003374 10.7326/0003-4819-149-6-200809160-00005 10.1080/21505594.2020.1794410 10.1146/annurev.publhealth.21.1.193 10.1016/j.jclinepi.2020.04.016 10.1016/S0140-6736(20)31030-8 10.1093/ije/dyw060 10.1097/TP.0000000000001671 10.7326/M17-1907 10.1136/bmj.m1313 10.1002/pds.4963 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2021 COPYRIGHT 2021 BioMed Central Ltd. 2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: The Author(s) 2021 – notice: COPYRIGHT 2021 BioMed Central Ltd. – notice: 2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| CorporateAuthor | on behalf of Public Health Scotland COVID-19 Health Protection Study Group Public Health Scotland COVID-19 Health Protection Study Group |
| CorporateAuthor_xml | – name: on behalf of Public Health Scotland COVID-19 Health Protection Study Group – name: Public Health Scotland COVID-19 Health Protection Study Group |
| DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7QL 7U9 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR C1K CCPQU COVID DWQXO FYUFA GHDGH H94 K9. M0S M1P M7N PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
| DOI | 10.1186/s12916-021-01907-8 |
| DatabaseName | Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Bacteriology Abstracts (Microbiology B) Virology and AIDS Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central Environmental Sciences and Pollution Management ProQuest One Community College Coronavirus Research Database ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Medical Database ProQuest Algology Mycology and Protozoology Abstracts (Microbiology C) ProQuest Central Premium ProQuest One Academic (New) ProQuest Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China Environmental Sciences and Pollution Management ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) Health & Medical Research Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) Virology and AIDS Abstracts ProQuest One Academic Eastern Edition Coronavirus Research Database ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic Publicly Available Content Database MEDLINE |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: PIMPY name: Publicly Available Content Database url: http://search.proquest.com/publiccontent sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Statistics Public Health |
| EISSN | 1741-7015 |
| EndPage | 11 |
| ExternalDocumentID | oai_doaj_org_article_bcd8259477a244fba8cad6ec07cb16fa PMC7897516 A653635339 33612113 10_1186_s12916_021_01907_8 |
| Genre | Journal Article |
| GeographicLocations | Scotland United Kingdom--UK |
| GeographicLocations_xml | – name: Scotland – name: United Kingdom--UK |
| GroupedDBID | --- 0R~ 23N 2WC 4.4 53G 5GY 5VS 6J9 6PF 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAWTL ABDBF ABUWG ACGFO ACGFS ACIHN ACPRK ACUHS ADBBV ADRAZ ADUKV AEAQA AENEX AFKRA AFPKN AFRAH AHBYD AHMBA AHYZX ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CS3 DIK DU5 E3Z EAD EAP EAS EBD EBLON EBS EMB EMK EMOBN ESX F5P FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO IHR IHW INH INR ITC KQ8 M1P M48 MK0 M~E O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PJZUB PPXIY PQQKQ PROAC PSQYO PUEGO RBZ RNS ROL RPM RSV SMD SOJ SV3 TR2 TUS UKHRP WOQ WOW XSB AAYXX AFFHD CITATION -5E -5G -A0 -BR 3V. ACRMQ ADINQ ALIPV C24 CGR CUY CVF ECM EIF NPM 7QL 7U9 7XB 8FK AZQEC C1K COVID DWQXO H94 K9. M7N PKEHL PQEST PQUKI PRINS 7X8 5PM |
| ID | FETCH-LOGICAL-c704t-792e9136b5b6b20253f1948a2c00f5e5cb006674b88b6bba838cd5cbc34fb6893 |
| IEDL.DBID | DOA |
| ISICitedReferencesCount | 46 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000621214100001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1741-7015 |
| IngestDate | Mon Nov 10 04:30:22 EST 2025 Tue Nov 04 02:04:49 EST 2025 Sun Nov 09 14:22:11 EST 2025 Wed Oct 08 14:21:43 EDT 2025 Tue Nov 11 10:20:42 EST 2025 Tue Nov 04 17:55:20 EST 2025 Thu May 22 21:24:08 EDT 2025 Thu Jan 02 22:58:04 EST 2025 Sat Nov 29 04:08:22 EST 2025 Tue Nov 18 22:49:33 EST 2025 Sat Sep 06 07:29:20 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | COVID-19 Pharmacoepidemiology Polypharmacy Opioids Gabapentinoids Overprescribing Antipsychotic agents Proton pump inhibitors |
| Language | English |
| License | Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c704t-792e9136b5b6b20253f1948a2c00f5e5cb006674b88b6bba838cd5cbc34fb6893 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ORCID | 0000-0002-5217-1034 |
| OpenAccessLink | https://doaj.org/article/bcd8259477a244fba8cad6ec07cb16fa |
| PMID | 33612113 |
| PQID | 2502641214 |
| PQPubID | 42775 |
| PageCount | 11 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_bcd8259477a244fba8cad6ec07cb16fa pubmedcentral_primary_oai_pubmedcentral_nih_gov_7897516 proquest_miscellaneous_2492286093 proquest_journals_2502641214 gale_infotracmisc_A653635339 gale_infotracacademiconefile_A653635339 gale_healthsolutions_A653635339 pubmed_primary_33612113 crossref_citationtrail_10_1186_s12916_021_01907_8 crossref_primary_10_1186_s12916_021_01907_8 springer_journals_10_1186_s12916_021_01907_8 |
| PublicationCentury | 2000 |
| PublicationDate | 2021-02-22 |
| PublicationDateYYYYMMDD | 2021-02-22 |
| PublicationDate_xml | – month: 02 year: 2021 text: 2021-02-22 day: 22 |
| PublicationDecade | 2020 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | BMC medicine |
| PublicationTitleAbbrev | BMC Med |
| PublicationTitleAlternate | BMC Med |
| PublicationYear | 2021 |
| Publisher | BioMed Central BioMed Central Ltd Springer Nature B.V BMC |
| Publisher_xml | – name: BioMed Central – name: BioMed Central Ltd – name: Springer Nature B.V – name: BMC |
| References | JK Aronson (1907_CR1) 2020; 369 SC Appleton (1907_CR5) 2014; 15 JM Connors (1907_CR10) 2020; 135 G Trifirò (1907_CR18) 2010; 152 M Maclure (1907_CR8) 2000; 21 P Bruzzi (1907_CR7) 1985; 122 G Mancia (1907_CR9) 2020; 382 AD Wiese (1907_CR17) 2018; 168 SG Weiner (1907_CR24) 2017; 101 S Alvarez-Madrazo (1907_CR4) 2016; 45 PM McKeigue (1907_CR3) 2020; 17 PE Alexander (1907_CR11) 2020; 123 1907_CR2 EJ Edelman (1907_CR14) 2019; 179 1907_CR6 J Hallas (1907_CR15) 2014; 275 H Luo (1907_CR21) 2018; 18 J Shi (1907_CR20) 2020; 11 M Sarkar (1907_CR19) 2008; 149 L Pasina (1907_CR22) 2020; 29 E Ramirez (1907_CR23) 2010; 5 FJ de Abajo (1907_CR25) 2020; 395 1907_CR16 1907_CR12 1907_CR13 |
| References_xml | – volume: 5 start-page: 288 year: 2010 ident: 1907_CR23 publication-title: Curr Clin Pharmacol doi: 10.2174/157488410793352067 – volume: 152 start-page: 418 year: 2010 ident: 1907_CR18 publication-title: Ann Intern Med doi: 10.7326/0003-4819-152-7-201004060-00006 – ident: 1907_CR2 – volume: 275 start-page: 581 year: 2014 ident: 1907_CR15 publication-title: J Intern Med doi: 10.1111/joim.12186 – volume: 179 start-page: 297 year: 2019 ident: 1907_CR14 publication-title: JAMA Intern Med doi: 10.1001/jamainternmed.2018.6101 – volume: 15 start-page: 58 year: 2014 ident: 1907_CR5 publication-title: BMC Fam Pract doi: 10.1186/1471-2296-15-58 – volume: 382 start-page: 2431 year: 2020 ident: 1907_CR9 publication-title: N Engl J Med doi: 10.1056/NEJMoa2006923 – volume: 18 start-page: 537 year: 2018 ident: 1907_CR21 publication-title: BMC Health Serv Res doi: 10.1186/s12913-018-3358-5 – ident: 1907_CR13 doi: 10.23889/ijpds.v4i3.1230 – volume: 122 start-page: 904 year: 1985 ident: 1907_CR7 publication-title: Am J Epidemiol doi: 10.1093/oxfordjournals.aje.a114174 – ident: 1907_CR12 doi: 10.1016/j.japh.2017.06.002 – volume: 17 start-page: 1003374 year: 2020 ident: 1907_CR3 publication-title: PLoS Med doi: 10.1371/journal.pmed.1003374 – volume: 149 start-page: 391 year: 2008 ident: 1907_CR19 publication-title: Ann Intern Med doi: 10.7326/0003-4819-149-6-200809160-00005 – volume: 135 start-page: 2033—40 year: 2020 ident: 1907_CR10 publication-title: Blood J Am Soc Hematol – volume: 11 start-page: 941 year: 2020 ident: 1907_CR20 publication-title: Virulence doi: 10.1080/21505594.2020.1794410 – volume: 21 start-page: 193 year: 2000 ident: 1907_CR8 publication-title: Annu Rev Public Health doi: 10.1146/annurev.publhealth.21.1.193 – volume: 123 start-page: 120 year: 2020 ident: 1907_CR11 publication-title: J Clin Epidemiol doi: 10.1016/j.jclinepi.2020.04.016 – ident: 1907_CR16 – volume: 395 start-page: 1705 year: 2020 ident: 1907_CR25 publication-title: Lancet (London, England) doi: 10.1016/S0140-6736(20)31030-8 – volume: 45 start-page: 714 year: 2016 ident: 1907_CR4 publication-title: Int J Epidemiol doi: 10.1093/ije/dyw060 – volume: 101 start-page: 678 year: 2017 ident: 1907_CR24 publication-title: Transplantation doi: 10.1097/TP.0000000000001671 – volume: 168 start-page: 396 year: 2018 ident: 1907_CR17 publication-title: Ann Intern Med doi: 10.7326/M17-1907 – volume: 369 start-page: m1313 year: 2020 ident: 1907_CR1 publication-title: BMJ doi: 10.1136/bmj.m1313 – ident: 1907_CR6 – volume: 29 start-page: 461 year: 2020 ident: 1907_CR22 publication-title: Pharmacoepidemiol Drug Saf doi: 10.1002/pds.4963 |
| SSID | ssj0025774 |
| Score | 2.5049984 |
| Snippet | Background
The objective of this study was to investigate the relation of severe COVID-19 to prior drug prescribing.
Methods
Severe cases were defined by entry... The objective of this study was to investigate the relation of severe COVID-19 to prior drug prescribing. Severe cases were defined by entry to critical care... Background The objective of this study was to investigate the relation of severe COVID-19 to prior drug prescribing. Methods Severe cases were defined by entry... The objective of this study was to investigate the relation of severe COVID-19 to prior drug prescribing. Severe cases were defined by entry to critical care... The objective of this study was to investigate the relation of severe COVID-19 to prior drug prescribing.BACKGROUNDThe objective of this study was to... Abstract Background The objective of this study was to investigate the relation of severe COVID-19 to prior drug prescribing. Methods Severe cases were defined... |
| SourceID | doaj pubmedcentral proquest gale pubmed crossref springer |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 51 |
| SubjectTerms | Aged Aged, 80 and over Analgesics Anticholinergics Antipsychotic agents Antipsychotics Biomedicine Case-Control Studies Comorbidity Complications and side effects Coronaviruses COVID-19 COVID-19 - chemically induced COVID-19 - diagnosis COVID-19 - epidemiology Critical care Critical Care - trends Diabetes Dose-Response Relationship, Drug Drug dosages Drug Prescriptions Drugs Dyskinesia Epidemics Exposure Female Gabapentinoids Gastrointestinal system Humans Intensive care Male Medicine Medicine & Public Health Middle Aged Morbidity Morphine Narcotics Opioids Pharmacoepidemiology Pneumonia Polypharmacy Population Prescribing Prescription drugs Primary care Proton pump inhibitors Psychotropic drugs Psychotropic Drugs - adverse effects Psychotropic Drugs - therapeutic use Public health Ratios Research Article Risk Scotland - epidemiology Severe acute respiratory syndrome coronavirus 2 Severity of Illness Index Statistics |
| SummonAdditionalLinks | – databaseName: Health & Medical Collection dbid: 7X7 link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpR3bbtMw1IKBEBLiMm6BAUZC4gGs1U7iCy-olE0gwYZgTH2zYscpk6akpC3S_p5jx2nJEHvhNT62Yp-7fS4IvXDcgZNRMWIELwgQhSWFlYqYlPl3NymcC3VmP4mDAzmdqi_xwm0Rwyp7mRgEddlYf0e-C6oadDdlNHs7_0l81yj_uhpbaFxGV3zbbE_nYrpxuHKwbfpEGcl3F6DbqA-59Q40OIVEDpRRqNn_t2T-QzWdD5s893YaVNL-rf_dzG10MxqjeNxRzx10ydXb6Nrn-Ny-jW50l3q4y1W6i5Z96BxuKgwq1bUOTw6PP74nVOFlg-fN6dm8q4V9hou6xD7KFsQSeN8zPyWmfLXNHBYt29Vs8QaDAYq_7o0nR-Tb5PAIW9CqJMbP41D79h76vr93NPlAYtsGYsUoWxKhmFM05SY33DDAQlpRlcmC2dGoyl1uTYiszYyUAGAKmUpbwlebZpXhYD_dR1t1U7uHCMM6XLiKUlOaTGaVymBFpkrqjDTGpAmiPf60jTXNfWuNUx18G8l1h3MNONcB51om6NV6zryr6HEh9DtPFmtIX407fGjamY7MrY0twdFWmRAFWEsVbMkWJXd2JKyhvCoS9MwTle5SW9cyRY95noLBl6YqQS8DhJcqsAFbxOQIOAZfn2sAuTOABGlgh8M9xekojRZ6Q24Jer4e9jN9hF3tmhXAZIoxyYE_E_Sgo_P1ptPU15mjMCIGHDA4leFIffIj1CoXUomc8gS97nll81v_PvVHF-_iMbrOAhczwtgO2lq2K_cEXbW_lieL9mmQAb8BedRhTA priority: 102 providerName: ProQuest – databaseName: SpringerLINK Contemporary 1997-Present dbid: RSV link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Zb9QwELagIMQL9xEoYCQkHsDq2k588LYsrUCCFrWl6psVO86yUpWssrtI_feMnQNSDgle47EVj-eUZz4j9MILD0lGyYiVIicgFI7kTmliOQv3bkp6H3FmP8r9fXV6qj93TWGrvtq9v5KMljqqtRI7K_BMNBTMhvQXUjqiLqMr4O5UeLDh8OhkSLMyiGj69pjfzhu5oIjU_6s9_skhXSyWvHBjGh3R3s3_28ItdKMLPPG0lZTb6JKv7qBrn7qr9bto3ZfF4brE4C594_Hs4OTDO0I1Xtd4WZ-dL1uc63OcVwUOFbRgciCznocpXTtXUy8XDhfNZr56gyG4xIe709kxOZodHGMHHpN0tfE44treQ1_2do9n70n3JANxcpKuidTMa8qFzaywDHjNS6pTlTM3mZSZz5yNVbOpVQoIbK64cgV8dTwtrYDY6D7aqurKP0QY1hHSl5TawqYqLXUKKzJdUG-VtZYniPanZFyHVx6ezTgzMW9RwrTsNMBOE9lpVIJeDXOWLVrHX6nfhsMfKAPSdvxQN3PTKa6xroAkWqdS5hAJlbAllxfCu4l0looyT9CzIDqmbVsd7IWZioxDMMe5TtDLSBEsBmzA5V3jA7AhYG-NKLdHlKDpbjzci6fpLM3KQAgLMS1lNE3Q82E4zAzVc5WvN0CTasaUAN1L0INWmodNcx4w5CiMyJGcj7gyHqkWXyMOuVRaZlQk6HUv7T9-689cf_Rv5I_RdRYVhhHGttHWutn4J-iq-7ZerJqnUfO_A0FMUrM priority: 102 providerName: Springer Nature |
| Title | Relation of severe COVID-19 to polypharmacy and prescribing of psychotropic drugs: the REACT-SCOT case-control study |
| URI | https://link.springer.com/article/10.1186/s12916-021-01907-8 https://www.ncbi.nlm.nih.gov/pubmed/33612113 https://www.proquest.com/docview/2502641214 https://www.proquest.com/docview/2492286093 https://pubmed.ncbi.nlm.nih.gov/PMC7897516 https://doaj.org/article/bcd8259477a244fba8cad6ec07cb16fa |
| Volume | 19 |
| WOSCitedRecordID | wos000621214100001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVADU databaseName: BioMed Central Open Access Free customDbUrl: eissn: 1741-7015 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0025774 issn: 1741-7015 databaseCode: RBZ dateStart: 20030101 isFulltext: true titleUrlDefault: https://www.biomedcentral.com/search/ providerName: BioMedCentral – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1741-7015 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0025774 issn: 1741-7015 databaseCode: DOA dateStart: 20030101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 1741-7015 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0025774 issn: 1741-7015 databaseCode: M~E dateStart: 20030101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1741-7015 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0025774 issn: 1741-7015 databaseCode: 7X7 dateStart: 20090101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1741-7015 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0025774 issn: 1741-7015 databaseCode: BENPR dateStart: 20090101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Publicly Available Content Database customDbUrl: eissn: 1741-7015 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0025774 issn: 1741-7015 databaseCode: PIMPY dateStart: 20090101 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest – providerCode: PRVAVX databaseName: SpringerLink Contemporary (1997 - Present) customDbUrl: eissn: 1741-7015 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0025774 issn: 1741-7015 databaseCode: RSV dateStart: 20031201 isFulltext: true titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22 providerName: Springer Nature |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3db9MwELdgIMQL4nMERjESEg9grXYSf_DWlU5MYl3VlWk8WbHjjEpTUvUDaf89ZycpyxDwwkskx2cruQ_fnXz-GaG3jjtIMgpGjOAZAaWwJLNSERMzv-8mhXMBZ_aLGI_l-bmaXLvqy9eE1fDANeP2jc0hiVGJEBl4osJk0mY5d7YvrKG8CKFRX6g2mWpSrRSimvaIjOT7K_Bq1Bfb-tQZ0kEiO24ooPX_viZfc0o3CyZv7JoGZ3T4ED1ookg8qL_-Ebrlysfo3nGzT_4ErdsaN1wVGHyfWzo8PDk7-kSowusKL6rLq0UNWn2FszLHvhwW1g9Iky_8kOZs1rJazC3Ol5uL1UcMkSKejgbDGTkdnsywBfdHmkJ3HEBqn6Kvh6PZ8DNp7lcgVvSTNRGKOUVjblLDDQOmxQVVicyY7feL1KXWhBLYxEgJBMD5WNoc3toY5MAh0HmGdsqqdM8Rhnm4cAWlJjeJTAqVwIxM5dQZaYyJI0RbdmvbgI_7OzAudUhCJNe1iDSISAcRaRmh99sxixp646_UB16KW0oPmx1egDLpRpn0v5QpQq-9Duj6DOrW-PWApzFEZnGsIvQuUHjzhx-wWXOKAdjggbQ6lHsdSjBb2-1u9Uw3y8ZKQzwKASplNInQm223H-lL4UpXbYAmUYxJDoYUod1aLbc_HcceEI5Cj-gobIcr3Z5y_j2AigupREp5hD60qv3rs_7M9Rf_g-sv0X0WTJMRxvbQznq5ca_QXftjPV8te-i2OBfhKXvozsFoPJn2grFDa3J0PPkGrenp2U_kKFZQ |
| linkProvider | Directory of Open Access Journals |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V3db9MwELemgQAJ8TG-AoMZCcQDWKudxHaQECrdplXrOsQK6puJHWdMmpKStqD-U_yNnPPRkiH2tgde47MVX86_u4vvA6EXlltwMlJGtOAxAaEwJDYyItpn7t5NCmvLOrMDMRzK8Tj6uIZ-NbkwLqyywcQSqJPcuH_k26CqQXdTRoP3k-_EdY1yt6tNC41KLA7s4ie4bNN3_R34vi8Z29sd9fZJ3VWAGNEJZkREzEbU5zrUXIPrH_opOPIyZqbTSUMbupb1nItASwkEOpa-NAk8NX6Qai5d8SWA_CuA48I5e2K8cvBCsKWaxBzJt6egS6kL8XUOOzihRLaUX9kj4G9N8IcqPB-mee6utlSBe7f_N-bdQbdqYxt3q9NxF63ZbANdO6zDCTbQzeqnJa5yse6hWRMaiPMUg8lgC4t7R1_6O4RGeJbjSX62mFS1vhc4zhLsoogBdjWwy02pU9qKfAKLJsX8ZPoWg4GNP-12eyNy3DsaYQNWA6nzA3BZ2_c--nwpPHiA1rM8s48QhnW4sCmlOtGBDNIogBVZlFCrpdba9xBt5EWZuma7ax1ypkrfTXJVyZgCGVOljCnpodfLOZOqYsmF1B-cGC4pXbXx8kFenKgavJQ2iQQ3ORAiBmswhS2ZOOHWdITRlKexh7acEKsqdXeJmarLQx8MWt-PPPSqpHCoCRswcZ38AWxw9cdalJstSkA70x5uJFzVaDtVK_H20PPlsJvpIggzm8-BJogYkxzwx0MPq3O13LTvuzp6FEZE68S1uNIeyU6_lbXYhYxESLmH3jRnc_Va_-b644t3sYWu748OB2rQHx48QTdYiSCMMLaJ1mfF3D5FV82P2em0eFbiD0ZfL_vM_gYWNr1e |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELagoIoL70KgUCMhcQCrayexHW7LtisqyraiperNih1nWalKVtksUv89Y-dBUx4S4hqPo3gynof8zWeEXltuocjIGdGCpwSMwpDUyITokLlzNyms9Tyzh2I2k-fnyfGVLn6Pdu-OJJueBsfSVNS7yyxvtrjkuyuIUtSBZ10pDOUdkTfRrcgB6V29fnLWl1wxZDddq8xv5w3CkWft_9U3XwlO14GT105PfVCa3vv_5dxHd9uEFI8bC3qAbtjiIdr83B65P0J1B5fDZY4hjNrK4snR2cEeoQmuS7wsLy6XDf_1JU6LDDtkLbgiqLjnbkrb5lWVy4XBWbWer95jSDrxl_3x5JScTI5OsYFISlrMPPZ8t4_R1-n-6eQjaa9qIEaMopqIhNmEhlzHmmsGeg9zmkQyZWY0ymMbG-3RtJGWEgR0KkNpMnhqwijXHHKmLbRRlIV9ijC8hwubU6ozHckoTyJ4I0syarXUWocBot0fU6blMXfXaVwoX89Irhp1KlCn8upUMkBv-znLhsXjr9IfnCH0ko6B2z8oq7lqN7TSJoPiOomESCFDymFJJs24NSNhNOV5GqAdZ0aqaWft_Yga8ziEJC8MkwC98RLOk8ACTNo2RIAaHCfXQHJ7IAkewAyHO1NVrQdaKUhtIdeljEYBetUPu5kOVVfYcg0yUcKY5LAnA_Sksex-0WHouOUojIiBzQ-0MhwpFt88P7mQiYgpD9C7zvJ_ftaftf7s38R30Obx3lQdHsw-PUd3mN87jDC2jTbqam1foNvme71YVS-9Q_gBua5eew |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Relation+of+severe+COVID-19+to+polypharmacy+and+prescribing+of+psychotropic+drugs%3A+the+REACT-SCOT+case-control+study&rft.jtitle=BMC+medicine&rft.au=Paul+M.+McKeigue&rft.au=Sharon+Kennedy&rft.au=Amanda+Weir&rft.au=Jen+Bishop&rft.date=2021-02-22&rft.pub=BMC&rft.eissn=1741-7015&rft.volume=19&rft.issue=1&rft.spage=1&rft.epage=11&rft_id=info:doi/10.1186%2Fs12916-021-01907-8&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_bcd8259477a244fba8cad6ec07cb16fa |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1741-7015&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1741-7015&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1741-7015&client=summon |